Agenus, Inc. (AGEN)
8.085
+0.10
(+1.19%)
USD |
NASDAQ |
Sep 02, 16:00
8.085
0.00 (0.00%)
After-Hours: 17:49
Agenus Research and Development Expense (TTM) : 57.69M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 57.69M |
| March 31, 2026 | 69.64M |
| December 31, 2025 | 79.34M |
| September 30, 2025 | 105.60M |
| June 30, 2025 | 123.06M |
| March 31, 2025 | 133.13M |
| December 31, 2024 | 155.53M |
| September 30, 2024 | 188.48M |
| June 30, 2024 | 198.86M |
| March 31, 2024 | 221.38M |
| December 31, 2023 | 234.57M |
| September 30, 2023 | 221.12M |
| June 30, 2023 | 215.69M |
| March 31, 2023 | 201.37M |
| December 31, 2022 | 186.69M |
| September 30, 2022 | 186.90M |
| June 30, 2022 | 183.82M |
| March 31, 2022 | 184.37M |
| December 31, 2021 | 178.61M |
| September 30, 2021 | 160.69M |
| June 30, 2021 | 149.89M |
| March 31, 2021 | 142.93M |
| December 31, 2020 | 142.62M |
| September 30, 2020 | 143.88M |
| June 30, 2020 | 157.88M |
| Date | Value |
|---|---|
| March 31, 2020 | 164.57M |
| December 31, 2019 | 168.34M |
| September 30, 2019 | 167.54M |
| June 30, 2019 | 151.26M |
| March 31, 2019 | 135.29M |
| December 31, 2018 | 124.60M |
| September 30, 2018 | 120.44M |
| June 30, 2018 | 116.38M |
| March 31, 2018 | 112.93M |
| December 31, 2017 | 116.13M |
| September 30, 2017 | 110.24M |
| June 30, 2017 | 106.04M |
| March 31, 2017 | 102.57M |
| December 31, 2016 | 94.97M |
| September 30, 2016 | 86.94M |
| June 30, 2016 | 83.85M |
| March 31, 2016 | 86.26M |
| December 31, 2015 | 70.44M |
| September 30, 2015 | 59.86M |
| June 30, 2015 | 46.65M |
| March 31, 2015 | 27.10M |
| December 31, 2014 | 22.35M |
| September 30, 2014 | 18.22M |
| June 30, 2014 | 16.83M |
| March 31, 2014 | 14.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Novavax, Inc. | 335.42M |
| Amgen, Inc. | 7.638B |
| Anika Therapeutics, Inc. | 27.45M |
| BioCryst Pharmaceuticals, Inc. | 195.46M |
| Imunon, Inc. | 8.191M |